A recent study in an orthotopic mouse model of early-stage KRAS-driven NSCLC found changes to the tumor microenvironment with treatments using anti-PD-1, which, with further investigation, may serve as useful predictive markers for disease response to treatment [27]. Here, PDCD1 is linked to non-small cell lung carcinoma.